|
시장보고서
상품코드
2149253
골반장기탈출증 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)Pelvic Organ Prolapse Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034 |
||||||
골반장기탈출증(POP) 시장 성장요인
세계 골반장기탈출증(POP) 시장 규모는 2025년 13억 1,000만 달러로 평가되며, 2026년 13억 8,000만 달러에서 2034년까지 22억 6,000만 달러로 성장하여, 예측 기간 동안 연평균 성장률(CAGR) 6.3%를 기록할 것으로 전망됩니다. 북미는 선진적인 의료 인프라, 골반저 장애 진단 건수의 증가, 그리고 최소침습 치료법의 보급에 힘입어 2025년에는 34.35%의 점유율로 시장을 주도했습니다.
골반장기탈출증은 방광, 자궁, 직장 등 골반 내 장기를 지탱하는 근육이나 조직이 약해져, 이러한 장기가 정상 위치에서 벗어나면서 발생합니다. 이 시장은 인구 고령화, 출산에 따른 골반저 장애, 비만, 갱년기, 검진 체계의 확충, 그리고 이용 가능한 치료법에 대한 인식 제고와 같은 요인들로부터 혜택을 받고 있습니다. 또한, 각 의료기기 제조사들은 환자의 편안함을 높이고, 합병증을 줄이며, 회복 기간을 단축하기 위한 목적으로 개선된 임플란트, 페서리 및 최소침습 기술의 개발을 추진하고 있습니다.
시장의 주요 포인트
세계 골반장기탈출증(POP) 시장은 2025년 13억 1,000만 달러에서 2026년에는 13억 8,000만 달러로 확대되어, 2034년까지 22억 6,000만 달러에 달할 것으로 예측되며, 연평균 성장률(CAGR)은 6.3%가 될 전망입니다. 2025년에는 북미가 34.35%의 시장 점유율을 차지하며 선두를 유지했습니다. 2026년에는 외과적 치료가 시장의 59.8%를 차지할 것으로 예상되는 반면, 전방 구획 탈출증은 48.7%를 차지할 것으로 전망됩니다.
시장 역학
시장 촉진요인
고령 여성의 골반저 장애로 인한 부담 증가
노화, 출산, 폐경, 비만, 자궁 적출술, 만성 기침 및 신체적으로 격렬한 활동이 골반저 장애의 원인이 되고 있습니다. 평균 수명의 연장에 따라 검진 및 치료가 필요한 여성의 수가 증가하고 있습니다. 선별 검사의 발전과 첨단 치료 시스템 또한 시장 확대를 뒷받침하고 있습니다.
시장 억제요인
임플란트를 이용한 복원술에 대한 신중한 도입
질 내 메시 및 기타 합성 지지재 사용에 대한 신중한 태도는 여전히 시장 확대의 제약요인으로 작용하고 있습니다. 임상적 검토, 장기적 예후에 대한 우려, 전문적인 훈련의 필요성, 그리고 자가 조직이나 임플란트를 사용하지 않는 치료법의 선호 등이 새로운 임플란트 제품의 보급을 지연시킬 가능성이 있습니다.
시장의 기회
최소침습적이고 장기 보존형 치료에 대한 수요 증가
복강경 수술 및 로봇 수술에 대한 선호도 증가, 질 복원 기술의 발전, 그리고 착용감이 우수한 페서리의 등장이 새로운 기회를 창출하고 있습니다. 2025년 5월, 메디플러스는 보다 개인화된 비수술적 지원을 제공하기 위해 POPY 페서리 라인업에 5가지 사이즈를 추가했습니다.
시장 동향
환자 중심의 골반저 관리에 대한 관심이 증가
치료에 있어서는 골반저 물리치료, 생활습관 개선, 배뇨 기능 관리, 교육, 심리적 지원을 결합한 접근법이 점점 더 보편화되고 있습니다. 또한, 디지털 골반저 건강 플랫폼과 환자 개개인에 맞춘 운동 프로그램도 주목을 받고 있습니다.
시장의 과제
진단 지연, 사회적 편견, 전문의 진료 접근성 제한
수치심이나 문화적 편견, 그리고 탈출증이 노화나 출산에 따른 자연스러운 결과라는 인식이 진단 지연을 초래할 수 있습니다. 비뇨기과·산부인과 전문의나 골반저 전문 외과 의사의 수가 제한적인 점도 고도의 치료를 받는 데 제약을 주는 요인이 되고 있습니다.
세분화 분석
제품 유형별
시장 세분화에서는 합성 메시 임플란트, 생체 이식편, 봉합 키트, 페서리, 기타로 구분됩니다. 합성 메시 임플란트는 재건 수술에서의 사용에 힘입어 2025년에는 가장 큰 시장 점유율을 차지했습니다. 페서리 부문은 연평균 성장률(CAGR) 6.9%로 성장할 것으로 예측됩니다.
치료 유형별
시장은 외과적 치료와 비외과적 치료로 분류됩니다. 2025년에는 외과적 치료가 주류를 차지했으며, 2026년에는 59.8%의 점유율을 유지할 것으로 예상됩니다. 이는 최소침습적 천골 질 고정술, 천추 고정술 및 질 전벽 고정술에 힘입은 결과입니다. 비수술적 치료는 연평균 성장률(CAGR) 5.2%로 성장할 것으로 예측됩니다.
골반장기탈출증의 종류별
2025년에는 전방 탈출증이 시장을 독점할 것으로 보이며, 방광 탈출증의 높은 유병률을 반영하여 2026년에는 48.7%를 차지할 것으로 예상됩니다. 후방 탈출증은 연평균 성장률(CAGR) 6.7%로 성장할 것으로 예측됩니다.
최종사용자별
병원, 전문 클리닉, 기타가 주요 최종사용자 부문을 구성하고 있습니다. 병원은 2025년에 시장을 독점하고 있으며, 첨단 인프라와 수술 역량을 바탕으로 2026년에는 58.8%를 차지할 것으로 예상됩니다. 전문 클리닉은 연평균 성장률(CAGR) 6.9%로 성장할 것으로 예측됩니다.
지역별 전망
북미
북미는 여전히 주요 지역으로, 2025년에는 4억 5,000만 달러에 달했습니다. 미국 시장은 첨단 골반저 치료와 진단 건수 증가에 힘입어 2026년에는 4억 1,000만 달러에 달할 것으로 추정됩니다.
유럽
유럽은 2026년에 3억 7,000만 달러에 달하며, 연평균 성장률(CAGR) 5.4%로 성장할 것으로 예측됩니다. 2026년 영국, 독일, 프랑스의 시장 규모는 각각 6,000만 달러,8,000만 달러,5,000만 달러로 추산됩니다.
아시아태평양
아시아태평양은 2026년에 3억 6,000만 달러에 달할 것으로 예상됩니다. 중국과 인도는 각각 1억 2,000만 달러,8,000만 달러로 추산됩니다.
라틴아메리카 및 중동 및 아프리카
라틴아메리카는 2026년에 8,000만 달러에 달할 것으로 예상되는 반면, GCC 시장은 3,000만 달러에 달할 것으로 전망됩니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 역학
제4장 주요 인사이트
제5장 세계의 골반장기탈출증 시장 분석, 인사이트, 예측, 2021-2034년
제6장 북미의 골반장기탈출증 시장 분석, 인사이트, 예측, 2021-2034년
제7장 유럽의 골반장기탈출증 시장 분석, 인사이트, 예측, 2021-2034년
제8장 아시아태평양의 골반장기탈출증 시장 분석, 인사이트, 예측, 2021-2034년
제9장 라틴아메리카의 골반장기탈출증 시장 분석, 인사이트, 예측, 2021-2034년
제10장 중동 및 아프리카의 골반장기탈출증 시장 분석, 인사이트, 예측, 2021-2034년
제11장 경쟁 분석
KSM 26.10.22Growth Factors of pelvic organ prolapse (POP) Market
The global pelvic organ prolapse (POP) market size was valued at USD 1.31 billion in 2025 and is projected to grow from USD 1.38 billion in 2026 to USD 2.26 billion by 2034, exhibiting a CAGR of 6.3% during the forecast period. North America dominated the market with a 34.35% share in 2025, supported by advanced healthcare infrastructure, increasing diagnosis of pelvic floor disorders, and the availability of minimally invasive treatment options.
Pelvic organ prolapse occurs when the muscles and tissues supporting pelvic organs such as the bladder, uterus, or rectum weaken and allow these organs to shift from their normal position. The market is benefiting from population aging, childbirth-related pelvic floor disorders, obesity, menopause, improved screening, and growing awareness of available treatments. Medical device companies are also developing improved implants, pessaries, and minimally invasive technologies designed to improve patient comfort, reduce complications, and shorten recovery time.
MARKET KEY TAKEAWAYS
The global POP market is expected to increase from USD 1.31 billion in 2025 to USD 1.38 billion in 2026 and reach USD 2.26 billion by 2034, registering a 6.3% CAGR. North America held the leading 34.35% market share in 2025. Surgical treatment is expected to account for 59.8% in 2026, while anterior compartment prolapse is projected to represent 48.7%.
MARKET DYNAMICS
MARKET DRIVERS
Rising Burden of Pelvic Floor Disorders in Aging Women
Increasing age, childbirth, menopause, obesity, hysterectomy, chronic coughing, and physically demanding activities contribute to pelvic floor disorders. Growing life expectancy is increasing the number of women requiring evaluation and treatment. Improved screening and advanced treatment systems are also supporting market expansion.
MARKET RESTRAINTS
Cautious Adoption of Implant-Based Repair Techniques
Cautious use of transvaginal meshes and other synthetic support materials remains a restraint. Clinical scrutiny, concerns regarding long-term outcomes, specialized training requirements, and preference for native-tissue or non-implant approaches can slow adoption of newer implantable products.
MARKET OPPORTUNITIES
Growing Demand for Minimally Invasive and Organ-Preserving Treatments
Increasing preference for laparoscopic and robotic procedures, improved vaginal repair techniques, and comfortable pessaries is creating opportunities. In May 2025, Mediplus expanded its POPY pessary range with five additional sizes to provide more individualized non-surgical support.
MARKET TRENDS
Increasing Focus on Patient-Centered Pelvic Floor Care
Treatment is increasingly combining pelvic floor physiotherapy, lifestyle modification, continence management, education, and psychological support. Digital pelvic health platforms and customized exercise programs are also becoming more prominent.
MARKET CHALLENGES
Underdiagnosis, Stigma, and Limited Specialist Access
Embarrassment, cultural stigma, and the perception that prolapse is a normal consequence of aging or childbirth can delay diagnosis. Limited availability of urogynecologists and specialized pelvic floor surgeons also restricts access to advanced treatment.
SEGMENTATION ANALYSIS
By Product Type
The market is segmented into synthetic mesh implants, biological grafts, suture kits, pessaries, and others. Synthetic mesh implants held the largest share in 2025, supported by their use in reconstructive procedures. The pessaries segment is projected to grow at a 6.9% CAGR.
By Treatment Type
The market is divided into surgical and non-surgical treatment. Surgical treatment dominated in 2025 and is expected to hold 59.8% in 2026, supported by minimally invasive sacrocolpopexy, sacrospinous fixation, and pectopexy. Non-surgical treatment is projected to grow at a 5.2% CAGR.
By Prolapse Type
Anterior compartment prolapse dominated the market in 2025 and is expected to account for 48.7% in 2026, reflecting the high prevalence of cystocele. Posterior compartment prolapse is projected to grow at a 6.7% CAGR.
By End User
Hospitals, specialty clinics, and others constitute the major end-user segments. Hospitals dominated in 2025 and are expected to hold 58.8% in 2026, supported by advanced infrastructure and surgical capabilities. Specialty clinics are projected to grow at a 6.9% CAGR.
REGIONAL OUTLOOK
North America
North America remained the leading region, reaching USD 0.45 billion in 2025. The U.S. market is estimated at USD 0.41 billion in 2026, supported by advanced pelvic floor treatments and increasing diagnosis.
Europe
Europe is projected to reach USD 0.37 billion in 2026, growing at a 5.4% CAGR. The U.K., Germany, and France are estimated at USD 0.06 billion, USD 0.08 billion, and USD 0.05 billion, respectively, in 2026.
Asia Pacific
Asia Pacific is expected to reach USD 0.36 billion in 2026. China and India are estimated at USD 0.12 billion and USD 0.08 billion, respectively.
Latin America and Middle East & Africa
Latin America is expected to reach USD 0.08 billion in 2026, while the GCC market is projected at USD 0.03 billion.
COMPETITIVE LANDSCAPE
Major companies include Boston Scientific Corporation, Coloplast A/S, Johnson & Johnson Services Inc., CooperSurgical Inc., BD, Caldera Medical, MedGyn Products, Integra LifeSciences, Symmetry Surgical, KARL STORZ, and B. Braun Melsungen AG. Companies are focusing on product launches, regulatory approvals, collaborations, commercialization, and expansion into emerging markets.
KEY INDUSTRY DEVELOPMENTS
In June 2025, Escala Medical raised USD 4.5 million for commercialization of its FDA-approved Mendit device. In May 2025, Mediplus expanded its POPY pessary range. In September 2024, ConTIPI Medical partnered with EVERSANA for ProVate commercialization. In February 2022, Medtronic received FDA approval for InterStim X.
REPORT COVERAGE
The report covers the global pelvic organ prolapse market across product type, treatment type, prolapse type, and end user. It includes market dynamics, regional analysis, competitive landscape, product developments, partnerships, approvals, and key strategies adopted by major companies.
CONCLUSION
The global pelvic organ prolapse market is projected to grow from USD 1.31 billion in 2025 to USD 1.38 billion in 2026 and USD 2.26 billion by 2034, at a 6.3% CAGR. Increasing diagnosis of pelvic floor disorders, an aging female population, minimally invasive procedures, patient-centered care, and improved pessary and implant technologies are expected to support market expansion. At the same time, cautious adoption of implant-based treatments, underdiagnosis, stigma, and limited specialist access remain important market considerations.
Segmentation By Product Type, Treatment Type, Prolapse Type, Application, End-user, and Region
By Product Type
- Synthetic Mesh Implants
- Biological Grafts
- Suture Kits
- Pessaries
- Others
By Treatment Type
- Surgical Treatment
- Sacrocolpopexy
- Sacrohysteropexy
- Others
- Non-surgical Treatment
- Pessary Management
- Pelvic Floor Physical Therapy
- Others
By Prolapse Type
- Anterior Compartment Prolapse
- Posterior Compartment Prolapse
- Others
By End-user
- Hospitals
- Specialty Clinics
- Others
By Region
- North America (By Product Type, Treatment Type, Prolapse Type, End-user, and Country)
- U.S. (By Product Type)
- Canada (By Product Type)
- Europe (By Product Type, Treatment Type, Prolapse Type, End-user, and Country/Sub-region)
- Germany (By Product Type)
- U.K. (By Product Type)
- France (By Product Type)
- Spain (By Product Type)
- Italy (By Product Type)
- Scandinavia (By Product Type)
- Rest of Europe (By Product Type)
- Asia Pacific (By Product Type, Treatment Type, Prolapse Type, End-user, and Country/Sub-region)
- China (By Product Type)
- Japan (By Product Type)
- India (By Product Type)
- Australia (By Product Type)
- Southeast Asia (By Product Type)
- Rest of Asia Pacific (By Product Type)
- Latin America (By Size, Procedure, End-user, and Country/Sub-region)
- Brazil (By Product Type)
- Mexico (By Product Type)
- Rest of Latin America (By Product Type)
- Middle East & Africa (By Product Type, Treatment Type, Prolapse Type, End-user, and Country/Sub-region)
- GCC (By Product Type)
- South Africa (By Product Type)
- Rest of the Middle East & Africa (By Product Type)
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Technological Advancements in Pelvic Organ Prolapse (POP)
- 4.2. New Product Launches, Key Players
- 4.3. Key Industry Developments - Mergers, Acquisitions & Partnerships
5. Global Pelvic Organ Prolapse (POP) Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Product Type
- 5.1.1. Synthetic Mesh Implants
- 5.1.2. Biological Grafts
- 5.1.3. Suture Kits
- 5.1.4. Pessaries
- 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast - By Treatment Type
- 5.2.1. Surgical Treatment
- 5.2.1.1. Sacrocolpopexy
- 5.2.1.2. Sacrohysteropexy
- 5.2.1.3. Others
- 5.2.2. Non-surgical Treatment
- 5.2.2.1. Pessary Management
- 5.2.2.2. Pelvic Floor Physical Therapy
- 5.2.2.3. Others
- 5.2.1. Surgical Treatment
- 5.3. Market Analysis, Insights and Forecast - By Prolapse Type
- 5.3.1. Anterior Compartment Prolapse
- 5.3.2. Posterior Compartment Prolapse
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast - By End-user
- 5.4.1. Hospitals
- 5.4.2. Specialty Clinics
- 5.4.3. Others
- 5.5. Market Analysis, Insights and Forecast - By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East and Africa
6. North America Pelvic Organ Prolapse (POP) Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Product Type
- 6.1.1. Synthetic Mesh Implants
- 6.1.2. Biological Grafts
- 6.1.3. Suture Kits
- 6.1.4. Pessaries
- 6.1.5. Others
- 6.2. Market Analysis, Insights and Forecast - By Treatment Type
- 6.2.1. Surgical Treatment
- 6.2.1.1. Sacrocolpopexy
- 6.2.1.2. Sacrohysteropexy
- 6.2.1.3. Others
- 6.2.2. Non-surgical Treatment
- 6.2.2.1. Pessary Management
- 6.2.2.2. Pelvic Floor Physical Therapy
- 6.2.2.3. Others
- 6.2.1. Surgical Treatment
- 6.3. Market Analysis, Insights and Forecast - By Prolapse Type
- 6.3.1. Anterior Compartment Prolapse
- 6.3.2. Posterior Compartment Prolapse
- 6.3.3. Others
- 6.4. Market Analysis, Insights and Forecast - By End-user
- 6.4.1. Hospitals
- 6.4.2. Specialty Clinics
- 6.4.3. Others
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.1.1. By Product Type
- 6.5.2. Canada
- 6.5.2.1. By Product Type
- 6.5.1. U.S.
7. Europe Pelvic Organ Prolapse (POP) Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Product Type
- 7.1.1. Synthetic Mesh Implants
- 7.1.2. Biological Grafts
- 7.1.3. Suture Kits
- 7.1.4. Pessaries
- 7.1.5. Others
- 7.2. Market Analysis, Insights and Forecast - By Treatment Type
- 7.2.1. Surgical Treatment
- 7.2.1.1. Sacrocolpopexy
- 7.2.1.2. Sacrohysteropexy
- 7.2.1.3. Others
- 7.2.2. Non-surgical Treatment
- 7.2.2.1. Pessary Management
- 7.2.2.2. Pelvic Floor Physical Therapy
- 7.2.2.3. Others
- 7.2.1. Surgical Treatment
- 7.3. Market Analysis, Insights and Forecast - By Prolapse Type
- 7.3.1. Anterior Compartment Prolapse
- 7.3.2. Posterior Compartment Prolapse
- 7.3.3. Others
- 7.4. Market Analysis, Insights and Forecast - By End-user
- 7.4.1. Hospitals
- 7.4.2. Specialty Clinics
- 7.4.3. Others
- 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.5.1. U.K.
- 7.5.1.1. By Product Type
- 7.5.2. Germany
- 7.5.2.1. By Product Type
- 7.5.3. France
- 7.5.3.1. By Product Type
- 7.5.4. Spain
- 7.5.4.1. By Product Type
- 7.5.5. Italy
- 7.5.5.1. By Product Type
- 7.5.6. Scandinavia
- 7.5.6.1. By Product Type
- 7.5.7. Rest of Europe
- 7.5.7.1. By Product Type
- 7.5.1. U.K.
8. Asia Pacific Pelvic Organ Prolapse (POP) Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Product Type
- 8.1.1. Synthetic Mesh Implants
- 8.1.2. Biological Grafts
- 8.1.3. Suture Kits
- 8.1.4. Pessaries
- 8.1.5. Others
- 8.2. Market Analysis, Insights and Forecast - By Treatment Type
- 8.2.1. Surgical Treatment
- 8.2.1.1. Sacrocolpopexy
- 8.2.1.2. Sacrohysteropexy
- 8.2.1.3. Others
- 8.2.2. Non-surgical Treatment
- 8.2.2.1. Pessary Management
- 8.2.2.2. Pelvic Floor Physical Therapy
- 8.2.2.3. Others
- 8.2.1. Surgical Treatment
- 8.3. Market Analysis, Insights and Forecast - By Prolapse Type
- 8.3.1. Anterior Compartment Prolapse
- 8.3.2. Posterior Compartment Prolapse
- 8.3.3. Others
- 8.4. Market Analysis, Insights and Forecast - By End-user
- 8.4.1. Hospitals
- 8.4.2. Specialty Clinics
- 8.4.3. Others
- 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.5.1. Japan
- 8.5.1.1. By Product Type
- 8.5.2. Australia
- 8.5.2.1. By Product Type
- 8.5.3. China
- 8.5.3.1. By Product Type
- 8.5.4. India
- 8.5.4.1. By Product Type
- 8.5.5. Southeast Asia
- 8.5.5.1. By Product Type
- 8.5.6. Rest of Asia Pacific
- 8.5.6.1. By Product Type
- 8.5.1. Japan
9. Latin America Pelvic Organ Prolapse (POP) Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Product Type
- 9.1.1. Synthetic Mesh Implants
- 9.1.2. Biological Grafts
- 9.1.3. Suture Kits
- 9.1.4. Pessaries
- 9.1.5. Others
- 9.2. Market Analysis, Insights and Forecast - By Treatment Type
- 9.2.1. Surgical Treatment
- 9.2.1.1. Sacrocolpopexy
- 9.2.1.2. Sacrohysteropexy
- 9.2.1.3. Others
- 9.2.2. Non-surgical Treatment
- 9.2.2.1. Pessary Management
- 9.2.2.2. Pelvic Floor Physical Therapy
- 9.2.2.3. Others
- 9.2.1. Surgical Treatment
- 9.3. Market Analysis, Insights and Forecast - By Prolapse Type
- 9.3.1. Anterior Compartment Prolapse
- 9.3.2. Posterior Compartment Prolapse
- 9.3.3. Others
- 9.4. Market Analysis, Insights and Forecast - By End-user
- 9.4.1. Hospitals
- 9.4.2. Specialty Clinics
- 9.4.3. Others
- 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.5.1. Brazil
- 9.5.1.1. By Product Type
- 9.5.2. Mexico
- 9.5.2.1. By Product Type
- 9.5.3. Rest of Latin America
- 9.5.3.1. By Product Type
- 9.5.1. Brazil
10. Middle East and Africa Pelvic Organ Prolapse (POP) Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Product Type
- 10.1.1. Synthetic Mesh Implants
- 10.1.2. Biological Grafts
- 10.1.3. Suture Kits
- 10.1.4. Pessaries
- 10.1.5. Others
- 10.2. Market Analysis, Insights and Forecast - By Treatment Type
- 10.2.1. Surgical Treatment
- 10.2.1.1. Sacrocolpopexy
- 10.2.1.2. Sacrohysteropexy
- 10.2.1.3. Others
- 10.2.2. Non-surgical Treatment
- 10.2.2.1. Pessary Management
- 10.2.2.2. Pelvic Floor Physical Therapy
- 10.2.2.3. Others
- 10.2.1. Surgical Treatment
- 10.3. Market Analysis, Insights and Forecast - By Prolapse Type
- 10.3.1. Anterior Compartment Prolapse
- 10.3.2. Posterior Compartment Prolapse
- 10.3.3. Others
- 10.4. Market Analysis, Insights and Forecast - By End-user
- 10.4.1. Hospitals
- 10.4.2. Specialty Clinics
- 10.4.3. Others
- 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.5.1. South Africa
- 10.5.1.1. By Product Type
- 10.5.2. GCC
- 10.5.2.1. By Product Type
- 10.5.3. Rest of Middle East and Africa
- 10.5.3.1. By Product Type
- 10.5.1. South Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2024)
- 11.2. Company Profiles
- 11.2.1. Boston Scientific Corporation
- 11.2.2. Coloplast A/S
- 11.2.3. Johnson & Johnson Services Inc.
- 11.2.4. CooperSurgical Inc.
- 11.2.5. BD
- 11.2.6. Caldera Medical
- 11.2.7. MedGyn Products
- 11.2.8. Integra LifeSciences
- 11.2.9. Symmetry Surgical
- 11.2.10. KARL STORZ
- 11.2.11. B. Braun Melsungen AG
